Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) Relative Strength Index (RSI) is 63.65, with weekly volatility at 4.40% and ATR at 1.07. The SUPN stock’s 52-week price range has touched low of $17.20 and a $34.29 high. Intraday shares traded counted 0.49 million, which was 5.05% higher than its 30-day average trading volume of 512.31K. Its shares traded lower over the last trading session, losing -1.84% on 06/17/21. The shares fell to a low of $31.75 before closing at $32.58. SUPN’s previous close was $33.19 while the outstanding shares total 52.93M. The firm has a beta of 1.25, a 12-month trailing P/E ratio of 15.76, and a growth ratio of 9.33.
Investors have identified the Drug Manufacturers – Specialty & Generic company Supernus Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $1.76 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Supernus Pharmaceuticals Inc. (SUPN) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 586.02 million total, with 240.81 million as their total liabilities.
SUPN were able to record 34.69 million as free cash flow during the 08/04/2021 quarter of the year, this saw their quarterly net cash flow reduce by -33.0 million. In cash movements, the company had a total of 36.2 million as operating cash flow.
Potential earnings growth for Supernus Pharmaceuticals Inc. (SUPN)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/04/2021 quarter of the year, Supernus Pharmaceuticals Inc. recorded a total of 130.93 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 27.46% coming in sequential stages and their sales for the 08/04/2021 quarter reducing by -9.64%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 14.95 million trying to sell their products during the last quarter, with the result yielding a gross income of 115.98 million. This allows shareholders to hold on to 52.93M with the recently reported earning now reading 0.11 cents per share. This is a figure that compared to analyst’s prediction for their 08/04/2021 (0.11 cents a share).
Having a look at the company’s valuation, the company is expected to record 1.22 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on SUPN sounds very interesting.
Is the stock of SUPN attractive?
In related news, Sr. V.P., Regulatory Affairs, Martin Tami Tillotson sold 3,125 shares of the company’s stock in a transaction that recorded on Apr 14. The sale was performed at an average price of 31.98, for a total value of 99,938. As the sale deal closes, the Sr. V.P., Regulatory Affairs, Martin Tami Tillotson now sold 3,125 shares of the company’s stock, valued at 93,702. Also, Executive Vice President & CMO, Schwabe Stefan K.F. sold 46,347 shares of the company’s stock in a deal that was recorded on Dec 21. The shares were price at an average price of 22.10 per share, with a total market value of 1,024,463. Following this completion of acquisition, the Executive Vice President & CMO, Schwabe Stefan K.F. now holds 53,653 shares of the company’s stock, valued at 1,173,264. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.50%.
3 out of 4 analysts covering the stock have rated it a Buy, while 1 have maintained a Hold recommendation on Supernus Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the SUPN stock. The 12-month mean consensus price target for the company’s shares has been set at $35.00.